Printer Friendly Version View printer-friendly version
<< Back
Mediclinic Intnl plc - Result of AGM
RNS Number : 0808M
Mediclinic International plc
26 July 2017
 

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC

JSE Share Code: MEI
NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

("Mediclinic", the "Company" or the "Group")

 

26 July 2017

 

ANNOUNCEMENT OF THE ANNUAL GENERAL MEETING POLL RESULTS

 

Mediclinic announces that at its Annual General Meeting ("AGM") held on 25 July 2017, all resolutions set out in the notice of the AGM were passed by the requisite majority of votes by shareholders by way of poll. The results of the poll for each resolution were as follows:

 



TOTAL SHARES VOTED

% OF ISSUED SHARE CAPITAL VOTED

VOTES FOR

%

VOTES AGAINST

%

VOTES WITHHELD


ORDINARY RESOLUTIONS








1.  

To receive the Company's financial statements and the reports by the Directors and auditors

643,346,097

87.26%

642,608,938

99.99%

211

0.01%

736,948

2.  

To approve the Directors' Remuneration Report

643,346,097

87.26%

618,212,690

96.25%

24,075,900

3.75%

1,057,507

3.  

To approve the amended Directors' Remuneration Policy

643,346,097

87.26%

614,711,926

95.95%

25,915,697

4.05%

2,718,474

4.  

To declare a final dividend of 4.70 pence per ordinary share

643,346,097

87.26%

642,966,257

99.99%

211

0.01%

379,629

5.  

To elect Jurgens Myburgh as a Director

643,346,097

87.26%

640,899,142

99.68%

2,060,463

0.32%

386,492

6.  

To re-elect Danie Meintjes as a Director

643,346,097

87.26%

642,864,882

99.99%

94,723

0.01%

386,492

7.  

To re-elect Dr Edwin Hertzog as a Director

643,346,097

87.26%

625,998,995

97.38%

16,833,567

2.62%

513,535

8.  

To re-elect Jannie Durand as a Director

643,346,097

87.26%

612,105,167

95.26%

30,444,213

4.74%

796,717

9.  

To re-elect Alan Grieve as a Director

643,346,097

87.26%

640,694,983

99.93%

445,220

0.07%

2,205,894

10.

To re-elect Seamus Keating as a Director

643,346,097

87.26%

641,082,006

99.99%

46,572

0.01%

2,217,519

11.

To re-elect Prof Dr Robert Leu as a Director

643,346,097

87.26%

641,083,644

99.99%

44,934

0.01%

2,217,519

12.

To re-elect Nandi Mandela as a Director

643,346,097

87.26%

642,901,226

99.99%

49,254

0.01%

395,617

13.

To re-elect Trevor Petersen as a Director

643,346,097

87.26%

632,937,299

98.72%

8,191,279

1.28%

2,217,519

14.

To re-elect Desmond Smith as a Director

643,346,097

87.26%

639,878,832

99.87%

836,521

0.13%

2,630,744

15.

To re-appoint PricewaterhouseCoopers LLP as auditors of the Company

643,346,097

87.26%

642,446,940

99.99%

3,656

0.01%

895,501

16.

To authorise the Audit and Risk Committee to determine the remuneration of the auditors

643,346,097

87.26%

642,417,589

99.98%

120,859

0.02%

807,649

17.

To authorise the Directors to make political donations

643,346,097

87.26%

566,825,468

89.04%

69,771,641

10.96%

6,748,988

18.

To authorise the Directors to allot ordinary shares

643,346,097

87.26%

527,047,324

82.04%

115,391,424

17.96%

907,349


SPECIAL RESOLUTIONS








19.

To authorise the Directors to dis-apply the statutory pre-emption rights

643,346,097

87.26%

583,771,316

91.13%

56,840,187

8.87%

2,734,594

20.

To authorise the Directors to dis-apply pre-emption rights for purposes of acquisitions or capital investments

643,346,097

87.26%

591,889,385

93.19%

43,253,058

6.81%

8,203,654

21.

To authorise the amendment to the Articles of Association

643,346,097

87.26%

641,126,245

99.99%

1,314

0.01%

2,218,538

22.

To approve the reduction in minimum notice period for general meetings (other than annual general meetings)

643,346,097

87.26%

617,065,427

96.43%

22,854,064

3.57%

3,426,606

 

 

 

 

 

VOTES OF SHAREHOLDERS EXCLUDING THE CONTROLLING SHAREHOLDER ON ELECTION AND RE-ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTORS

 


ORDINARY RESOLUTIONS

TOTAL SHARES VOTED

% OF ISSUED SHARE CAPITAL VOTED

VOTES FOR

%

VOTES AGAINST

%

VOTED WITHHELD

9.

To re-elect Alan Grieve as a Director

571,230,713

77.48%

568,579,599

99.92%

445,220

0.08%

2,205,894

10.

To re-elect Seamus Keating as a Director

571,230,713

77.48%

568,966,622

99.99%

46,572

0.01%

2,217,519

11.

To re-elect Prof Dr Robert Leu as a Director

571,230,713

77.48%

568,968,260

99.99%

44,934

0.01%

2,217,519

12.

To re-elect Nandi Mandela as a Director

571,230,713

77.48%

570,785,842

99.99%

49,254

0.01%

395,617

13.

To re-elect Trevor Petersen as a Director

571,230,713

77.48%

560,821,915

98.56%

8,191,279

1.44%

2,217,519

14.

To re-elect Desmond Smith as a Director

571,230,713

77.48%

567,763,448

99.85%

836,521

0.15%

2,630,744

 

Notes:

 

1.

Any proxy appointments giving discretion to the Chairman of the Meeting have been included in the "For" total.

 

2.

A vote "Withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.

 

3.

The Company's total ordinary shares in issue (total voting rights) as at 25 July 2017 was 737 243 810 ordinary shares of 10 pence each. Ordinary shareholders are entitled to one vote per ordinary share held.

 

4.

As the Company has a controlling shareholder, Remgro Limited, as defined in the Financial Conduct Authority's Listing Rules, each resolution to elect an independent non-executive director (resolutions 9 to 14) have under Listing Rule 9.2.2E been approved by a majority of the votes cast by:

(a) the shareholders of the Company as a whole; and

(b) the independent shareholders of the Company, that is, all the shareholders entitled to vote on each resolution, excluding the controlling shareholder.

 

In accordance with paragraph 9.6.2 of the Listing Rules, a copy of the resolutions passed at the meeting has been submitted to the National Storage Mechanism and will shortly be available for inspection at http://www.morningstar.co.uk/uk/NSM

 

The complete poll results and details of proxy votes lodged before the AGM will be available shortly on the Company's website at www.mediclinic.com.

 

About Mediclinic International plc

Mediclinic is an international private healthcare group with operating platforms in Southern Africa (South Africa and Namibia), Switzerland and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a LSE listed and UK-based private healthcare group.

 

Mediclinic comprises 74 hospitals and 37 clinics. Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 000 inpatient beds in total; Hirslanden operates 16 private acute care facilities and 4 clinics in Switzerland with more than 1 600 inpatient beds; and Mediclinic Middle East operates 6 hospitals and 31 clinics with more than 700 inpatient beds in the United Arab Emirates.

 

During February 2016, the combination of the Company (previously named Al Noor Hospitals Group plc), with operations mainly in Abu Dhabi in the United Arab Emirates, and Mediclinic International Limited was completed. Mediclinic International Limited was a South African based international private healthcare group founded in 1983 and listed on the JSE, the South African stock exchange, since 1986, with operations in South Africa, Namibia, Switzerland and the United Arab Emirates (mainly in Dubai). The combination resulted in the renaming of the enlarged group to Mediclinic International plc.

 

Mediclinic has a primary listing on the Main Market of the LSE, with secondary listings on the JSE in South Africa and the NSX in Namibia.

 

For further information, please contact:

Capita Company Secretarial Services Limited

Victoria Dalby

+44 (0)207 954 9600

 

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

ir@mediclinic.com

+44 (0)20 3786 8181

 

Media queries

FTI Consulting

Brett Pollard/Debbie Scott (UK)

+44 (0)20 3727 1000

Frank Ford (South Africa)

+27 (0)21 487 9000

 

Registered address: 1st Floor, 40 Dukes Place, London, EC3A 7NH, United Kingdom

Website: www.mediclinic.com

Corporate broker: Morgan Stanley & Co International plc

JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGSEEFAIFWSEFW

IMPORTANT DISCLAIMER

ACCESS TO THIS AREA OF THE WEBSITE MAY BE RESTRICTED UNDER SECURITIES LAWS, RULES OR REGULATIONS IN CERTAIN JURISDICTIONS. THIS NOTICE REQUIRES YOU TO CONFIRM CERTAIN MATTERS (INCLUDING THAT YOU ARE NOT RESIDENT OR PHYSICALLY PRESENT IN SUCH A JURISDICTION), BEFORE YOU MAY OBTAIN ACCESS TO THE INFORMATION ON THIS AREA OF THE WEBSITE. THESE MATERIALS ARE NOT DIRECTED AT OR TO BE ACCESSED BY, OR DISTRIBUTED OR DISSEMINATED TO, DIRECTLY OR INDIRECTLY, PERSONS RESIDENT OR PHYSICALLY LOCATED IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS, RULES OR REGULATIONS OF THAT JURISDICTION OR WOULD RESULT IN A REQUIREMENT TO COMPLY WITH CONSENT OR OTHER FORMALITY WHICH MEDICLINIC REGARDS AS UNDULY ONEROUS.

Combination of Mediclinic International Limited ("Mediclinic") and Al Noor Hospitals Group plc ("Al Noor") (the "Combination")

Access to the website

You are attempting to enter the part of the website that is designated for the publication of documents and information in connection with the Combination.

If you would like to view this part of the website, please read this notice carefully. This notice applies to all persons who view this part of the website and, depending on where you are located, may affect your rights or responsibilities. Mediclinic reserves the right to amend or update this notice at any time and you should, therefore, read it in full each time you visit the site. In addition, the contents of this part of the website may be amended at any time, in whole or in part, at the sole discretion of Mediclinic.

This part of the website contains electronic versions of materials relating to the Combination. The materials you are seeking to access are made available in good faith and for information purposes only and are subject to the terms and conditions set out below. Any person seeking to access this part of the website represents and warrants to Mediclinic that they are doing so for information purposes only.

To allow you to view information about the Combination, you must read this notice and then click "I ACCEPT". If you are unable to agree, you should click "I DECLINE" and you will not be able to view information about the Combination.

The Combination would be made by means of a scheme document to be published by Mediclinic which would contain the full terms and conditions of such Combination, including details on how it may be accepted. Any decision made in relation to the Combination should be made solely and only on the basis of the information provided in any such document.

Overseas jurisdictions

Viewing the materials you are seeking to access may be restricted under securities laws in certain jurisdictions. All persons who wish to view this part of the website must first satisfy themselves that they are not subject to any local requirements which prohibit or restrict them from doing so and should inform themselves about, and observe, any legal or regulatory requirements applicable in their jurisdiction.

These materials are not directed at or intended to be accessible by persons resident in any jurisdiction if to do so would constitute a violation of the relevant laws or regulations of that jurisdiction.

YOU SHOULD NOT, DIRECTLY OR INDIRECTLY, DOWNLOAD, MAIL, FORWARD, DISTRIBUTE, SEND OR SHARE THE INFORMATION OR DOCUMENTS CONTAINED ON THIS PART OF THE WEBSITE TO ANY PERSON. IN PARTICULAR, YOU SHOULD NOT, DIRECTLY OR INDIRECTLY, MAIL, FORWARD, DISTRIBUTE OR SEND THE INFORMATION OR DOCUMENTS CONTAINED THEREIN TO ANY JURISDICTION WHERE IT WOULD BE UNLAWFUL TO DO SO. MEDICLINIC AND ITS ADVISERS DO NOT ASSUME ANY LIABILITY FOR ANY VIOLATION BY ANY PERSON OF ANY OF THESE RESTRICTIONS.

It is your responsibility to satisfy yourself as to the full observance of any relevant laws and regulatory requirements. If you are in any doubt, you should click on “I DECLINE” below and exit this webpage.

Cautionary Note Regarding Forward-Looking Statements

This part of the website and the information contained in it may contain certain forward-looking statements with respect to the financial condition, results of operations and businesses of Mediclinic and the Mediclinic Group (being Mediclinic and its subsidiaries and subsidiary undertakings) and Al Noor and the Al Noor Group (being Al Noor and its subsidiaries and subsidiary undertakings) following the Combination. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in these statements. Forward-looking statements include, among other things, statements concerning the potential exposure of Mediclinic and the Mediclinic Group to market risks and statements expressing management's expectations, beliefs, estimates, forecasts, projections and assumptions, including as to future potential cost savings, synergies, earnings, cash flow and prospects. These forward-looking statements are identified by their use of terms and phrases such as "anticipate", "believe", "could", "estimate", "expect", "goals", "intend", "may", "objectives", "outlook", "plan", "probably", "project", "risks", "seek", "should", "target", "will" and similar terms and phrases. There are a number of factors that could affect the future operations of Mediclinic and the Mediclinic Group and Al Noor and the Al Noor Group post Combination and could cause those results to differ materially from those expressed in the forward-looking statements included in this part of the website. All forward-looking statements contained in this part of the website are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Each forward-looking statement speaks only as at the specified date of the relevant document within which the statement is contained. None of Mediclinic, the Mediclinic Group, Al Noor or the Al Noor Group undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information. In light of these risks, results could differ materially from those stated, implied or inferred from the forward-looking statements contained in this part of the website.

Responsibility

In relation to any Combination-related materials accessible on this area of the website please note any statement of responsibility contained therein.

The documents included in this part of the website issued or published by Mediclinic speak only at the specified date of the relevant document and Mediclinic has, and accepts, no responsibility or duty to update or revise such documents.

In relation to any such announcements or other Combination-related materials issued or published by Al Noor, or which relate to Al Noor and the Al Noor Group, that are accessible on this website, the only responsibility accepted by Mediclinic and its directors is for the correctness and fairness of its reproduction.

Neither the directors of Mediclinic, nor Mediclinic, nor any of their affiliated companies, have reviewed, and no such person is or shall be responsible for or accepts any liability in respect of, any information contained on any other website which may be linked to or from this part of the website.

Other

If you are in any doubt about the contents of this part of the website or the action you should take, you should seek your own financial advice from an appropriately authorised independent financial adviser.

This notice shall be governed by and construed in accordance with English law.

CONFIRMATION OF UNDERSTANDING AND ACCEPTANCE

If you are not able to give these confirmations, you should click on “I DECLINE” below and exit the webpage.